Alagille Syndrome

Overview

Alagille syndrome (ALGS) is a rare, usually autosomal-dominant genetic condition caused primarily by changes in JAG1 and, less often, NOTCH2, genes that help control Notch signaling during organ development. It can affect the liver, heart and blood vessels, kidneys, eyes, skeleton, and face; liver disease commonly results from having too few intrahepatic bile ducts, which impairs bile flow and can cause jaundice, severe itching, poor growth, and progressive liver damage. Severity is highly variable: some people have relatively mild disease, while others develop serious liver or heart complications in childhood. GeneReviews: Alagille Syndrome

Current care is multidisciplinary and treats complications rather than correcting the underlying genetic cause. It includes nutritional support and replacement of fat-soluble vitamins, medicines and bile-acid transport inhibitors to reduce cholestatic itching, specialist care for cardiac, kidney, vascular, eye, and developmental complications, and liver transplantation for refractory cholestasis or end-stage liver disease. GeneReviews: Alagille Syndrome

Scope of Recent Research (2020–present)

Research activity has grown from symptom control toward attempts to rebuild or preserve the liver’s bile-duct network by restoring the balance of JAG1–Notch signaling or modifying downstream developmental pathways. The field remains small, and the leading restorative approaches are still preclinical in cells, zebrafish, and mouse models; the completed human trials since 2020 have principally tested treatments for itching and bile-acid reduction rather than genetic cure. AAV-mediated SOX4 silencing JAG1-upregulating antisense oligonucleotides ASSERT odevixibat trial

Major Breakthroughs and Emerging Therapies

The most important recent advance is a 2025 AAV8 gene-silencing study targeting SOX4, a gene-regulating protein that appears overactive in ALGS liver tissue. Researchers delivered an artificial microRNA designed to lower Sox4 in mouse models with one nonworking Jag1 copy. A single treatment improved bile-duct density, fibrosis, necrosis, and other liver features; benefit persisted into adulthood in mice treated early, and treatment after liver injury had appeared also improved disease features. This is not gene replacement or gene editing: it is a liver-directed gene-regulation strategy intended to help residual developmental and regenerative capacity form a more functional biliary tree. AAV-mediated SOX4 silencing

A second strategy is to raise production of the healthy copy of JAG1. In 2025, investigators reported antisense oligonucleotides—short modified nucleic-acid medicines—that bind the untranslated region of JAG1 messenger RNA and increase translation into JAG1 protein. In patient-derived cells and Jag1-haploinsufficient mice, the optimized compound increased JAG1 protein and improved bile-duct development; treated newborn mice also showed favorable trends in bile acids, bilirubin, and triglycerides. This approach is especially attractive because most ALGS cases reflect insufficient JAG1 dosage rather than a need to replace both gene copies. JAG1-upregulating antisense oligonucleotides

A related RNA approach reduces POGLUT1, an enzyme that modifies JAG1 and influences its abundance and signaling. In 2023, an antisense oligonucleotide against Poglut1 improved bile-duct development, biliary-tree formation, and liver injury in several postnatal ALGS mouse models; cell experiments indicated that reduced POGLUT1 can increase JAG1 protein and JAG1-mediated signaling. POGLUT1 antisense therapy in ALGS mice Earlier work in zebrafish also found that a small-molecule putative Notch agonist increased Sox9 expression, improved bile-duct regeneration and cholestasis, and increased survival in mutant fish, providing proof of concept that carefully increasing Jagged/Notch/Sox9 activity could be restorative. Jagged/Notch/Sox9 rescue in zebrafish

A parallel diagnostic and precision-medicine effort is making it easier to identify which individual variants genuinely impair the pathway. A 2024 high-throughput assay tested 2,832 JAG1 variants for cell-surface expression and supplied evidence that reclassified many previously uncertain variants. In 2026, researchers also developed CRISPR-engineered “low-Notch-activity” cells that more cleanly measure JAG1–NOTCH2 signaling and enabled reclassification of a NOTCH2 variant as likely pathogenic. These platforms do not cure ALGS, but they can improve diagnosis, patient selection, and eventual matching of genotype-specific therapies to patients. High-throughput JAG1 variant testing Low-Notch-activity functional testing

Clinical Trials and Experimental Approaches

The largest recent clinical advances are bile-acid transport inhibitors, which improve major symptoms but do not repair the missing bile ducts or correct JAG1/NOTCH2 dysfunction. In Mirum Pharmaceuticals’ phase 2b ICONIC trial, maralixibat reduced serum bile acids and pruritus in children with ALGS; during randomized drug withdrawal, participants switched to placebo worsened while those continuing maralixibat maintained benefit. Gastrointestinal adverse events were common but generally mild to moderate. ICONIC maralixibat phase 2 trial

In Albireo Pharma/Ipsen’s completed phase 3 ASSERT trial, 52 participants were randomized to odevixibat or placebo for 24 weeks. Odevixibat produced significantly larger reductions in caregiver-reported scratching and serum bile acids than placebo; diarrhea was the most common treatment-emergent adverse event, and no participants discontinued treatment during the blinded period. ASSERT odevixibat phase 3 trial By contrast, the JAG1-raising antisense compounds, POGLUT1 suppression, small-molecule Notch activation, and AAV8-SOX4 silencing described above remain experimental preclinical approaches rather than established human ALGS therapies. AAV-mediated SOX4 silencing JAG1-upregulating antisense oligonucleotides

Methodologies and Scientific Approaches

Researchers are combining disease-relevant animal models with molecular measurements of bile-duct formation. These include Jag1-haploinsufficient and more severe Jag1/Sox9 mouse models, zebrafish with altered jagged gene dosage, patient-derived fibroblasts, liver histology, bile-duct-to-portal-vein counts, ink visualization of the biliary tree, blood chemistry, and single-cell RNA sequencing to identify vulnerable or rescuable cell states. AAV-mediated SOX4 silencing Jagged/Notch/Sox9 rescue in zebrafish

Delivery platforms reflect the proposed mechanism: GalNAc-conjugated antisense oligonucleotides are designed to improve liver uptake, while AAV8 vectors deliver a microRNA-like Sox4-silencing cassette to the liver, including through a hepatocyte-selective promoter. Biomarkers include serum bile acids, bilirubin, liver injury markers, bile-duct density, fibrosis, and pathway markers such as JAG1, NOTCH2, HES1, SOX9, and SOX4. JAG1-upregulating antisense oligonucleotides AAV-mediated SOX4 silencing

Leading Institutions and Funding

Baylor College of Medicine, UMass Chan Medical School’s Horae Gene Therapy Center, Cincinnati Children’s Hospital Medical Center, and the University of Cincinnati collaborated on the AAV8-SOX4 work. That study reported support including NIH grants R01DK132751 and R01NS076991, a Baylor training grant, Cincinnati Pediatric Cell Atlas support, and digestive-disease and imaging core funding. AAV-mediated SOX4 silencing Baylor College of Medicine, Cincinnati Children’s, and Ionis Pharmaceuticals also contributed to the POGLUT1 antisense study. POGLUT1 antisense therapy in ALGS mice

Industry has driven the symptom-focused clinical program: Mirum Pharmaceuticals sponsored the ICONIC maralixibat trial, while Albireo Pharma, now part of Ipsen, funded the ASSERT odevixibat trial. ICONIC maralixibat phase 2 trial ASSERT odevixibat phase 3 trial The Alagille Syndrome Alliance supports research infrastructure through the Global ALagille Alliance database and has operated a two-year Collaborative Scientific Research Grant worth $150,000. Alagille Syndrome Alliance research programs

Strengths, Limitations, and Challenges

The central strength of recent research is that several independent approaches now converge on a plausible disease-modifying goal: restore enough bile-duct development or regeneration to reduce cholestasis and avoid transplantation. The AAV-SOX4, JAG1-upregulation, POGLUT1-silencing, and Notch/SOX9 studies each showed improvement in biliary phenotypes in experimental models, strengthening the broader idea that postnatal intervention may still be possible despite ALGS being a developmental disorder. AAV-mediated SOX4 silencing JAG1-upregulating antisense oligonucleotides POGLUT1 antisense therapy in ALGS mice Jagged/Notch/Sox9 rescue in zebrafish

The limitations are substantial. Mouse and zebrafish bile-duct development, dosing windows, immune responses, and liver growth do not fully predict outcomes in children. Increasing JAG1/Notch signaling could affect multiple organs and carries theoretical safety concerns because Notch signaling regulates many normal developmental and adult tissue processes; conversely, the liver-specific AAV-SOX4 strategy may not address heart, vascular, kidney, eye, or skeletal disease. Antisense approaches must demonstrate durable delivery, appropriate dose control, and absence of unintended effects from changing JAG1 or POGLUT1 activity, while AAV-based treatment must address vector immunity, long-term safety, manufacturing, and equitable access. JAG1-upregulating antisense oligonucleotides AAV-mediated SOX4 silencing

Outlook and Future Directions

As of October 8, 2026, ALGS is not close to a proven whole-body genetic cure, but it is closer than before to a potential liver-directed disease-modifying therapy. The most important milestones to watch are replication of AAV-SOX4 and JAG1-enhancing results in additional models, formal toxicology and dose-ranging studies, evidence that treatment can help after established liver disease, and the first regulated human studies of a restorative—not merely anti-itch—therapy. A credible functional cure for liver disease would need to show durable rebuilding or preservation of bile ducts, improved liver outcomes, and acceptable long-term safety; it would still need to be paired with separate strategies for ALGS manifestations outside the liver. AAV-mediated SOX4 silencing JAG1-upregulating antisense oligonucleotides

References

• Alagille Syndrome — GeneReviews®, 2026.
• AAV-mediated silencing of Sox4 leads to long-term amelioration of liver phenotypes in mouse models of Alagille syndrome — Fox et al., 2025.
• Antisense oligonucleotide-mediated upregulation of Jag1 ameliorates liver disease phenotypes in a mouse model of Alagille syndrome — Zhang et al., 2025.
• ASO silencing of a glycosyltransferase, Poglut1, improves the liver phenotypes in mouse models of Alagille syndrome — Niknejad et al., 2023.
• Regenerative failure of intrahepatic biliary cells in Alagille syndrome rescued by elevated Jagged/Notch/Sox9 signaling — Zhao et al., 2022.
• Functional characterization of 2,832 JAG1 variants supports reclassification for Alagille syndrome — Gilbert et al., 2024.
• Improved functional JAG1 and NOTCH2 variant testing using low-Notch-activity cells — Böhmer et al., 2026.
• Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC) — Gonzales et al., 2021.
• Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT) — Ovchinsky et al., 2024.
• Alagille Syndrome Alliance research programs — Alagille Syndrome Alliance, 2026.